Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma by Liz Hanson | Aug 18, 2021 | Uncategorized
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors by Liz Hanson | Aug 13, 2021 | Uncategorized
